Immunotech Biopharm (HKSE:06978) Other Long-Term Liabilities : HK$65.42 Mil (As of Dec. 2024)

View and export this data going back to 2020. Start your Free Trial

What is Immunotech Biopharm Other Long-Term Liabilities?

Immunotech Biopharm's other long-term liabilities for the quarter that ended in Dec. 2024 was HK$65.42 Mil.

Immunotech Biopharm's quarterly other long-term liabilities increased from Dec. 2023 (HK$43.17 Mil) to Jun. 2024 (HK$71.01 Mil) but then declined from Jun. 2024 (HK$71.01 Mil) to Dec. 2024 (HK$65.42 Mil).

Immunotech Biopharm's annual other long-term liabilities declined from Dec. 2022 (HK$45.61 Mil) to Dec. 2023 (HK$43.17 Mil) but then increased from Dec. 2023 (HK$43.17 Mil) to Dec. 2024 (HK$65.42 Mil).

Immunotech Biopharm Other Long-Term Liabilities Historical Data

The historical data trend for Immunotech Biopharm's Other Long-Term Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Immunotech Biopharm Other Long-Term Liabilities Chart

Immunotech Biopharm Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Other Long-Term Liabilities

Get a 7-Day Free Trial

7.00

4.36

45.61

43.17

65.42

Immunotech Biopharm Semi-Annual Data
	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24	Dec24
Other Long-Term Liabilities	Get a 7-Day Free Trial								45.61	43.20	43.17	71.01	65.42

Immunotech Biopharm Other Long-Term Liabilities Calculation

Other Long-Term Liabilities are the other liabilities on the balance sheet that do not need to be repaid within the next 12 months, but still need to be repaid over time. For instance, on Wal-Mart's balance sheet, there are items called Long Term obligations under capital leases, deferred income taxes, and redeemable non-controlling interest. These are all Other Long-Term Liabilities.

Immunotech Biopharm Other Long-Term Liabilities Related Terms

Thank you for viewing the detailed overview of Immunotech Biopharm's Other Long-Term Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Immunotech Biopharm Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Immunotech Biopharm Ltd (HKSE:06978) » Definitions » Other Long-Term Liabilities

Comparable Companies

Traded in Other Exchanges

N/A

Address

No.1 Kangding Street, 8th Floor, Block 1, Guosheng Technology Park, Beijing Economic-technological Development Area, Beijing, CHN, 100176

Website

https://www.eaal.net

Immunotech Biopharm Ltd is a cellular immunotherapy biopharmaceutical company in China. The company is focused on the research, development, and commercialization of T-cell immunotherapy. Its product EAL is a multi-target cellular immunotherapy product for the treatment of various types of cancer. Its product pipeline features classes of cellular immunotherapy products, including both non-genetically modified and genetically modified products, as well as both multi-target and single-target products. Its other products include the CAR-T cell series and the TCR-T cell series.

Executives

Jung Hyun Chul
Evodevo Ltd
Yan Kaijing	2501 Other
Xi Zang Jia Ze Chuang Ye Tou Zi You Xian Gong Si	2101 Beneficial owner
Jiang Su Ji Chuan Kong Gu Ji Tuan You Xian Gong Si	2201 Interest of corporation controlled by you
Cao Longxiang	2201 Interest of corporation controlled by you
Cao Fei	2201 Interest of corporation controlled by you
Tian Jin Fu Hua De Ke Ji Kai Fa You Xian Gong Si	2501 Other
Yan Xijun	2501 Other
Wu Naifeng	2501 Other
Tasly (hong Kong) Pharmaceutical Investment Limited	2501 Other
Li Yunhui	2501 Other
Hua Run San Jiu Yi Yao Gu Fen You Xian Gong Si	2201 Interest of corporation controlled by you
China Resources Pharmaceutical Group Limited	2201 Interest of corporation controlled by you
China Resources Company Limited	2201 Interest of corporation controlled by you

Immunotech Biopharm Headlines

No Headlines